Several clinical trials are testing the BCL2 inhibitor venetoclax combined with chemotherapy or demethylating agents in ETP-ALL (ClinicalTrials.gov identifier: NCT03319901, NCT03826992; Chinese Clinical Trial Register: ChiCTR2200061708, ChiCTR2100048966). Here, BCL2 is linked to acute lymphoblastic leukemia.